Drugs / EMB07
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05607498 | Mar 2023 → Oct 2025 overdue | lymphoma | EpimAb Biotherapeutics (Suzhou)Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07432022 | Mar 2026 → Jun 2028 expected | aggressive B-cell non-Hodgkin lymphoma | Shanghai EpimAb Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMB-07 | “EMB-07 is a bispecific antibody targeting CD3 and receptor-tyrosine-kinase-like orphan receptor 1 [ROR1]” NCT07432022 ↗ |
| Route | Intravenous | “Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW)” NCT05607498 ↗ |
| Target | ROR1 | “EMB-07 is a bispecific antibody targeting CD3 and receptor-tyrosine-kinase-like orphan receptor 1 [ROR1]” NCT07432022 ↗ |